Michael J. Fox Foundation and Thermo Fisher Scientific Release Parkinson's Proteomic Dataset to Advance Biomarker Discovery
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Thermo Fisher Scientific have completed a comprehensive proteomic analysis of 5,500 samples from the Parkinson’s Precision Medicine Initiative (PPMI) study. This landmark observational study, launched in 2010, aims to identify biomarkers for Parkinson's disease risk, onset, and progression. The newly released dataset, which is open-source, allows researchers to measure thousands of proteins simultaneously, providing insights into how proteins and pathways change in Parkinson's patients compared to healthy individuals and different subgroups. This effort utilized Thermo Fisher's Olink Explore HT panel, a high-throughput proteomic platform, to analyze plasma and spinal fluid samples collected longitudinally from participants over several years. The data includes information from individuals with sporadic Parkinson's, those with risk factors like hyposmia and REM sleep behavior disorder, and individuals with genetic mutations associated with th...